Results 61 to 70 of about 12,336,620 (246)

Nanomedicine‐driven innovations in postoperative cancer immunotherapy: Remodeling tumor microenvironment and precision delivery strategies

BMEMat, EarlyView.
Nanomedicine‐Driven Strategies for Suppressing Postoperative Tumor Recurrence. This schematic illustrates three pivotal nanomedical strategies that synergistically counteract recurrence by targeting residual disease and the immunosuppressive tumor microenvironment within the surgical cavity.
Lisong Pang, Zhuomin Wang, Zhenhua Jin, Ahmed H. Ghonaim, Hengcheng Zhang, Xinyu You, Jinzhuo Ning, Jiaqing Cao, Yang Liu   +8 more
wiley   +1 more source

Chromosome aberrations evaluated by comparative genomic hybridization in B-cell chronic lymphocytic leukemia: correlation with CD38 expression

Haematologica, 2003
BACKGROUND AND OBJECTIVES: B-cell chronic lymphocytic leukemia (B-CLL) results from the accumulation of monoclonal CD5+ B cells. Despite its homogeneity at cellular level, B-CLL is clinically heterogeneous.
L Ottaggio, S Viaggi, A Zunino, S Zupo, E Rossi, M Spriano, A Abbondandolo, M Ferrarini   +7 more
doaj  

The expression and signalling patterns of CD180 toll like receptor in Chronic Lymphocytic Leukaemia (CLL) [PDF]

, 2019
Chronic lymphocytic leukaemia (CLL) is characterised by a progressive accumulation of mature CD5+CD20+CD23+ lymphocytes. Despite the remarkable progress in our understanding of the immunobiology of CLL, the aetiology of the disease remains unknown.
Sayed, U.
core   +1 more source

Coexistence of immunophenotypically normal and aberrant mast cells in patients with clonal mast cell diseases associates with more indolent subtypes and less severe disease characteristics

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Aberrant antigen expression on mast cells (MCs) is one of the most accurate diagnostic markers for clonal MC diseases (CMCD). Although the coexistence of normal and pathologic MCs is frequently seen, the disease characteristics associated with it have been minimally investigated.
Abdulrazzaq Alheraky, Kees Meijer, Marije Nijk, Saskia K. Klein, Hanneke N. G. Oude Elberink, Ido P. Kema, André B. Mulder   +6 more
wiley   +1 more source

Pathogen‐specific B‐cell receptors drive chronic lymphocytic leukemia by light‐chain‐dependent cross‐reaction with autoantigens

EMBO Molecular Medicine, 2017
Several lines of evidence indirectly suggest that antigenic stimulation through the B‐cell receptor (BCR) supports chronic lymphocytic leukemia (CLL) development.
Nereida Jiménez de Oya, Marco De Giovanni, Jessica Fioravanti, Rudolf Übelhart, Pietro Di Lucia, Amleto Fiocchi, Stefano Iacovelli, Dimitar G Efremov, Federico Caligaris‐Cappio, Hassan Jumaa, Paolo Ghia, Luca G Guidotti, Matteo Iannacone   +12 more
doaj   +1 more source

IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells [PDF]

, 2011
Tumor cells in chronic lymphocytic leukemia (CLL) are more prone to apoptosis when cultured ex vivo, because they lack prosurvival signals furnished in vivo via B-cell receptor (BCR)-dependent and -independent pathways.
C Vitale, F Pantaleoni, V Griggio, M Rigoni, Riganti, Chiara, M Ladetto, M Coscia, M Foglietta, Boccadoro, Mario, Massaia, Massimo, M Boccadoro, Pantaleoni F, M Massaia, Vitale, Candida, Griggio, Valentina, Ladetto, Marco, C Riganti, Castella, Barbara, Foglietta, Myriam, D Drandi, Bosia, Amalia, Peola, S, B Castella, Rigoni, Micol Maria, Coscia, Marta, S Peola, Peola S, A Bosia, Drandi, Daniela   +28 more
core   +1 more source

Neoadjuvant Cemiplimab for Resectable Locoregionally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series

Head &Neck, EarlyView.
ABSTRACT Introduction A Phase II trial demonstrated that neoadjuvant cemiplimab was associated with pathologic complete response (pCR) in 51% of patients with locoregionally advanced cutaneous squamous cell carcinoma (cuSCC). We evaluated real‐world radiographic and pathologic responses to neoadjuvant cemiplimab and assessed radiologic–pathologic ...
Whitney Jin, Ryan K. Rigsby, Kim Ely, Austin Hoke, Robert Sinard, Kyle Mannion, Jill Gilbert, Lindsay Mundy, Alexander Langerman, Sarah Rohde, Barbara Murphy, Eben Rosenthal, Mitra Mehrad, Michael C. Topf, Jennifer H. Choe   +14 more
wiley   +1 more source

Antigen receptors and somatic hypermutation in B-cell chronic lymphocytic leukemia with Richter's transformation

Haematologica, 2006
BACKGROUND AND OBJECTIVES: Activation-induced cytidine deaminase is essential for somatic hypermutation and class switch recombination of the immunoglobulin genes in B cells.
LA Smit, F van Maldegem, AW Langerak, CE van der Schoot, MJ de Wit, S Bea, E Campo, RJ Bende, CJ van Noesel   +8 more
doaj  

Allelotyping in B-cell chronic lymphocytic leukemia (B-CLL).

, 2004
B-cell chronic lymphocytic leukemia (B-CLL) is a heterogeneous malignant disease, both in terms of molecular abnormalities and clinical course. The most frequent chromosomal aberrations in B-CLL are deletions on 13q, 11q, and 17p, and trisomy 12, all of ...
Tobler A, Fey MF, Novak U
core   +1 more source

Risk of Developing Subsequent Primary Colorectal Cancers Among Non‐Colorectal Cancer Survivors: Implications for Prevention and Screening

International Journal of Cancer, EarlyView.
ABSTRACT Cancer survivors have an elevated risk of developing subsequent primary cancers, including colorectal cancer (CRC), and may benefit from tailored screening approaches to reduce incidence and morbidity. A retrospective cohort of adults diagnosed with cancer (excluding CRC) in Alberta, Canada from 2000 to 2021 who survived at least 6 months was ...
Dylan E. O'Sullivan, Robert J. Hilsden, Hannah Harsanyi, Matthew T. Warkentin, Kareem Jamani, Huiming Yang, Darren R. Brenner, Safiya Karim, Winson Y. Cheung, Yibing Ruan   +9 more
wiley   +1 more source